These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 21397482

  • 41. Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study.
    Yao W, Wang C, Zhong N, Han X, Wu C, Yan X, Chen P, Yang W, Henley M, Kramer B.
    Respirology; 2014 Feb; 19(2):231-238. PubMed ID: 24383720
    [Abstract] [Full Text] [Related]

  • 42. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
    Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K.
    Drugs; 2009 Jun 18; 69(9):1205-16. PubMed ID: 19537837
    [Abstract] [Full Text] [Related]

  • 43. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.
    Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ.
    Cochrane Database Syst Rev; 2015 Jan 10; 1(1):CD010139. PubMed ID: 25575340
    [Abstract] [Full Text] [Related]

  • 44. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D.
    Respir Med; 2013 Oct 10; 107(10):1558-67. PubMed ID: 23867808
    [Abstract] [Full Text] [Related]

  • 45. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar 10; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

  • 46. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
    Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, Brusasco V.
    Respir Med; 2012 Jan 10; 106(1):84-90. PubMed ID: 22035851
    [Abstract] [Full Text] [Related]

  • 47. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG.
    Respir Med; 2013 Jan 10; 107(1):107-11. PubMed ID: 23083839
    [Abstract] [Full Text] [Related]

  • 48. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
    Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K.
    Respir Med; 2008 Apr 10; 102(4):479-87. PubMed ID: 18258423
    [Abstract] [Full Text] [Related]

  • 49. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D, McBryan D, INVIGORATE investigators.
    Lancet Respir Med; 2013 Sep 10; 1(7):524-33. PubMed ID: 24461613
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.
    Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C, INSIST study group.
    Respir Med; 2011 May 10; 105(5):719-26. PubMed ID: 21367594
    [Abstract] [Full Text] [Related]

  • 52. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.
    Pulm Pharmacol Ther; 2007 May 10; 20(6):740-9. PubMed ID: 17088091
    [Abstract] [Full Text] [Related]

  • 53. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.
    Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP.
    Int J Chron Obstruct Pulmon Dis; 2011 May 10; 6():329-44. PubMed ID: 21697997
    [Abstract] [Full Text] [Related]

  • 54. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
    Jiang FM, Liang ZA, Zheng QL, Wang RC, Luo J, Li CT.
    Lung; 2013 Apr 10; 191(2):135-46. PubMed ID: 23306410
    [Abstract] [Full Text] [Related]

  • 55. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
    Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D.
    Pulm Pharmacol Ther; 2010 Jun 10; 23(3):165-71. PubMed ID: 20080201
    [Abstract] [Full Text] [Related]

  • 56. Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.
    Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP.
    Int J Chron Obstruct Pulmon Dis; 2012 Jun 10; 7():415-20. PubMed ID: 22848154
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Ten years of tiotropium: clinical impact and patient perspectives.
    Yohannes AM, Connolly MJ, Hanania NA.
    Int J Chron Obstruct Pulmon Dis; 2013 Jun 10; 8():117-25. PubMed ID: 23515335
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.